First Quadrant LP Holding in Biogen INC (BIIB) Has Lowered as Market Valuation Declined

April 17, 2018 - By reb123z

Biogen Inc. (NASDAQ:BIIB) LogoInvestors sentiment increased to 1.17 in Q4 2017. Its up 0.04, from 1.13 in 2017Q3. It improved, as 46 investors sold BIIB shares while 305 reduced holdings. 105 funds opened positions while 305 raised stakes. 180.65 million shares or 0.28% less from 181.16 million shares in 2017Q3 were reported. Los Angeles Capital Management And Equity owns 0.45% invested in Biogen Inc. (NASDAQ:BIIB) for 260,090 shares. Hbk Invs L P, a Texas-based fund reported 28,700 shares. Korea Investment reported 197,833 shares or 0.29% of all its holdings. Court Place Advsr Lc holds 1.86% of its portfolio in Biogen Inc. (NASDAQ:BIIB) for 14,128 shares. Etrade Capital Mngmt Limited Liability holds 8,327 shares or 0.09% of its portfolio. Philadelphia has invested 2.51% of its portfolio in Biogen Inc. (NASDAQ:BIIB). Ftb holds 0.51% of its portfolio in Biogen Inc. (NASDAQ:BIIB) for 16,562 shares. Ferguson Wellman Cap Management Incorporated holds 0.87% or 78,714 shares. Private Advisor Grp Incorporated Ltd Co reported 5,116 shares. Sumitomo Life Insur has 0.26% invested in Biogen Inc. (NASDAQ:BIIB). Gruss Inc owns 9,500 shares. Bnp Paribas Arbitrage reported 0.15% stake. Millennium Mgmt Ltd Limited Liability Company reported 0.02% stake. Stelac Advisory Lc owns 600 shares or 0.08% of their US portfolio. Ashfield Prtnrs Limited Liability Company stated it has 2,168 shares.

Since January 9, 2018, it had 0 buys, and 5 sales for $2.87 million activity. $1.92M worth of Biogen Inc. (NASDAQ:BIIB) shares were sold by PANGIA ROBERT W.

First Quadrant LP decreased its stake in Biogen Inc (BIIB) by 11.58% based on its latest 2017Q4 regulatory filing with the SEC. First Quadrant LP sold 12,661 shares as the company’s stock declined 17.01% with the market. The institutional investor held 96,698 shares of the biological products (no diagnostic substances) company at the end of 2017Q4, valued at $30.81M, down from 109,359 at the end of the previous reported quarter. First Quadrant LP who had been investing in Biogen Inc for a number of months, seems to be less bullish one the $56.59B market cap company. The stock increased 1.67% or $4.39 during the last trading session, reaching $267.5. About 979,601 shares traded. Biogen Inc. (NASDAQ:BIIB) has declined 3.66% since April 17, 2017 and is downtrending. It has underperformed by 15.21% the S&P500.

First Quadrant L P, which manages about $16.82B and $5.33 billion US Long portfolio, upped its stake in Copa Holdings Sa Class A (NYSE:CPA) by 106,383 shares to 206,110 shares, valued at $27.63M in 2017Q4, according to the filing. It also increased its holding in Harris Corp (NYSE:HRS) by 69,478 shares in the quarter, for a total of 87,278 shares, and has risen its stake in Arrow Electronics Inc (NYSE:ARW).

Analysts await Biogen Inc. (NASDAQ:BIIB) to report earnings on April, 24. They expect $5.94 earnings per share, up 14.23 % or $0.74 from last year’s $5.2 per share. BIIB’s profit will be $1.26 billion for 11.26 P/E if the $5.94 EPS becomes a reality. After $5.26 actual earnings per share reported by Biogen Inc. for the previous quarter, Wall Street now forecasts 12.93 % EPS growth.

Biogen Inc. (NASDAQ:BIIB) Ratings Coverage

Among 26 analysts covering Biogen (NASDAQ:BIIB), 18 have Buy rating, 0 Sell and 8 Hold. Therefore 69% are positive. Biogen had 49 analyst reports since October 18, 2017 according to SRatingsIntel. The rating was maintained by BMO Capital Markets on Thursday, January 25 with “Buy”. H.C. Wainwright maintained the shares of BIIB in report on Friday, January 26 with “Buy” rating. The firm has “Buy” rating given on Monday, October 23 by SunTrust. The stock has “Hold” rating by RBC Capital Markets on Wednesday, October 25. As per Monday, October 23, the company rating was maintained by Stifel Nicolaus. The company was downgraded on Thursday, January 25 by Credit Suisse. The firm has “Buy” rating by Piper Jaffray given on Thursday, January 18. The rating was upgraded by BMO Capital Markets on Wednesday, October 25 to “Outperform”. The rating was maintained by BMO Capital Markets on Tuesday, January 2 with “Buy”. Cantor Fitzgerald maintained Biogen Inc. (NASDAQ:BIIB) on Thursday, January 25 with “Hold” rating.

Biogen Inc. (NASDAQ:BIIB) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.

Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: